Your session is about to expire
← Back to Search
mRNA Vaccine for Nipah Virus
Study Summary
This trial is testing the safety of an experimental vaccine for Nipah virus. The virus is transmitted from animals to humans, and can cause serious symptoms like brain inflammation and death. There is no cure.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I do not have a spleen or my spleen does not work properly.I have not received any vaccines in the last 4 weeks.My high blood pressure is not well controlled.I have a history of seizures, with certain exceptions.I have not received any blood products in the last 16 weeks.My asthma is not well controlled.I can attend clinic visits for a year after my last treatment.I have a history of swelling attacks due to angioedema.My thyroid disease is not well controlled.I have diabetes (not including gestational diabetes).I am a healthy adult aged between 18 and 60.I have had Guillain-Barre Syndrome in the past.I am currently on medication to prevent or treat tuberculosis.I haven't taken strong immune or cancer drugs in the last 14 days.I have had cancer that might come back during the study.I am on a maintenance schedule for my allergy shots.My recent health check-up was normal and my BMI is between 18 and 35.I have had myocarditis or pericarditis in the past.I have a bleeding disorder or experience significant bleeding or bruising.
- Group 1: Group 1
- Group 2: Group 2
- Group 3: Group 3
- Group 4: Group 4
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have been recruited for this research project?
"Affirmative. Clinicaltrials.gov conveys that recruitment for this medical experiment is ongoing, having been posted on July 11th 2022 and last amended on October 28th 2022. The study aims to enlist 50 patients from a single site."
May I have the opportunity to partake in this clinical investigation?
"This medical experiment seeks to take in 50 individuals with nipah virus infection, aged 18-60. To be eligible for enrolment, applicants must have no prior conditions and maintain a healthy state of being as per the physical examination."
Does this research encompass adults aged 18 and up?
"The age requirements for this medical trial are between 18 and 60, inclusive."
Are there still vacancies available for individuals to participate in this clinical experiment?
"Clinicaltrials.gov confirms that this clinical investigation is still recruiting participants, as the study was initially posted on July 11th 2022 and recently updated on October 28th of the same year."
To what degree is mRNA -1215 a safe option for patients?
"Our group at Power assesses the safety of mRNA -1215 to be a 1 due to being in Phase 1. This means that only restricted evidence is available demonstrating its security and efficacy."
Share this study with friends
Copy Link
Messenger